Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-HD-MTX and HAART in AIDS-Related PCNSL
NCT00267865Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2006
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate and rituximab in primary central nervous system lymphoma (PCNSL), sponsored by National Cancer Institute. Primary endpoint: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects. Started Sep 2006; status: completed.
02
Drugs
methotrexaterituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00267865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267865.